Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Optimization Study for L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

NCT06336291 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT06336291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06336291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Optimization Study for L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 22, 2024
Completion date
June 30, 2026
Enrollment
90 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma